The New Jersey governor’s race is providing an early test for Democrats trying to navigate the thorny issues of immigration ...

Raghav Gulati and Ananyaa Sood shine at the Tommy Fleetwood International Pathway Series at Yas Links Abu Dhabi, securing top ...

This important study demonstrates the potential of synthetic gene circuits to detect and target aberrant RAS activity in cancer cell lines. The circuit design is novel and the evidence supporting the ...

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...

Six Democratic candidates vying for New Jersey’s governorship spoke directly to voters at the first debate of the season ...

New Jersey Democratic gubernatorial candidates vowed to protect illegal immigrants from President Trump’s ICE raids during ...

Newark Mayor Ras Baraka, 54, has led New Jersey's largest city since ... saying people are here illegally when we keep moving ...

(Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today ...

Alexander I. Spira, MD, PhD, FACP, discusses the next steps in the clinical development of zoldonrasib for patients with KRAS G12D pancreatic ductal adenocarcinoma based on preliminary findings.

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team will ...

These compounds, a fresh and innovative approach, disrupt critical RAS-dependent signaling pathways, offering a pathway to mitigate tumor growth and overcome resistance to standard therapies. This ...